


I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claim 1. (Previously Presented) A pharmaceutical composition comprising a compound of the formula:



wherein;


R₆ = S or O

R₃ is selected from the group consisting of C₁ – C₈ linear or branched alkyl; C₂ – C₈ linear or branched alkene; C₂ – C₈ linear or branched alkyne; C₃₋₈ cycloalkyl; Q; and K;

R₈ is selected from the group consisting of C₁ – C₈ linear or branched alkyl; C₂ – C₈ linear or branched alkene; C₂ – C₈ linear or branched alkyne; C₃₋₈ cycloalkyl; Q; and K;

wherein

Q has the general formula:



wherein;


$n = 0$ or 1 ;

$Z =$ a bond, CH_2 , NH , O or S ;

A and B can form a ring by adding 1-3 CH_2 groups when $Z = \text{CH}_2$, NH , O or S ; and

A and B are not in a ring when $Z =$ a bond, wherein A and B are independently selected from the group consisting of hydrogen; halogen; $\text{C}_1 - \text{C}_8$ alkyl; $\text{C}_1 - \text{C}_8$ alkoxy; $\text{C}_3 - \text{C}_8$ cycloalkyl; $\text{C}_3 - \text{C}_8$ cycloalkoxy; hydroxy; phenyl; benzyl; and benzyloxy; wherein said phenyl, benzyl and benzyloxy are optionally substituted with halogen, $\text{C}_1 - \text{C}_8$ alkyl, $\text{C}_1 - \text{C}_8$ alkoxy, $\text{C}_3 - \text{C}_8$ cycloalkyl, $\text{C}_3 - \text{C}_8$ cycloalkoxy and hydroxy;

K has the general formula:



wherein;

$n = 0$ or 1 ;

L and M are independently selected from the group consisting of hydrogen and methyl;

W is selected from the group consisting of Q ; hydroxy; benzyloxy optionally substituted with halogen, $\text{C}_1 - \text{C}_8$ alkyl, $\text{C}_1 - \text{C}_8$ alkoxy, $\text{C}_3 - \text{C}_8$ cycloalkyl, $\text{C}_3 - \text{C}_8$ cycloalkoxy and hydroxy; aryl; heteroaryl; and a heterocyclic ring;

provided that when R_3 is methyl, R_8 is not hydrogen;

and pharmaceutically acceptable salts thereof;

and at least one pharmaceutically acceptable excipient; said composition in the form of a solid dosage form selected from the group consisting of a tablet, gelcap, capsule, caplet, granule, and lozenge.

Claim 2. (Previously Presented) The pharmaceutical composition of claim 1 wherein R₃ is benzyl.

Claim 3. (Previously Presented) The pharmaceutical composition of claim 1 wherein R₃ is benzyl substituted with an alkoxy and a cycloalkoxy group.


Claim 4. (Previously presented) The compound of claim 1 wherein R₃ is benzyl substituted with benzyloxy.

Claim 5. (Currently Amended) The pharmaceutical composition of claim 1, wherein said compound is selected from the group consisting of:

- ~~3-butyl-hypoxanthine;~~
- ~~3-butyl-thiohypoxanthine;~~
- ~~3-ethyl-hypoxanthine;~~
- ~~3-ethyl-thiohypoxanthine;~~
- 3,8-diethyl-hypoxanthine;
- 3,8-diethyl-thiohypoxanthine;
- 3-ethyl-8-cyclopropyl-hypoxanthine;
- 3-ethyl-8-cyclopropyl-thiohypoxanthine;
- ~~3-propyl-hypoxanthine;~~
- ~~3-hexyl-hypoxanthine;~~
- ~~3-hexyl-thiohypoxanthine;~~
- ~~3-benzyl-hypoxanthine;~~
- ~~3-benzyl-thiohypoxanthine;~~
- ~~3-(4-methyl-butyl)-hypoxanthine;~~
- ~~3-(4-methyl-butyl)-thiohypoxanthine;~~
- ~~3-(2-methyl-butyl)-hypoxanthine;~~

~~3-(2-methyl-butyl)-thiohypoxanthine;~~
~~3-(3-cyclopentyloxy-4-methoxy-benzyl)-hypoxanthine;~~
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-hydroxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethylene)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(benzyloxymethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-methoxybenzyloxy)-1-methyl-
 ethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-
 ethyl)-hypoxanthine;
 3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;
 3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-hydroxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(1,3-benzdioxole-5-methyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(4-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-ethyl)-
 hypoxanthine;
 and pharmaceutically acceptable salts thereof.

Claim 6. (Withdrawn) A pharmaceutical composition comprising a compound of the formula:




wherein;

$R_6 = S$ or O

R_3 and R_8 are independently selected from the group consisting of $C_1 - C_8$ linear or branched alkyl; $C_2 - C_8$ linear or branched alkene; $C_2 - C_8$ linear or branched alkyne; C_{3-8} cycloalkyl; Q; and K; wherein

Q has the general formula:



wherein;


$n = 0$ or 1 ;

$Z =$ a bond, C , N , O or S ;

A and B can form a ring by adding 1-3 carbons when $Z = C$, N , O or S ; and

A and B are not in a ring when $Z =$ a bond, wherein A and B are independently selected from the group consisting of hydrogen; halogen; $C_1 - C_8$ alkyl; $C_1 - C_8$ alkoxy; $C_3 - C_8$ cycloalkyl; $C_3 - C_8$ cycloalkoxy; hydroxy; phenyl; benzyl; and benzyloxy; wherein said phenyl, benzyl and benzyloxy are optionally substituted with halogen, $C_1 - C_8$ alkyl, $C_1 - C_8$ alkoxy, $C_3 - C_8$ cycloalkyl, $C_3 - C_8$ cycloalkoxy and hydroxy;

K has the general formula:



wherein;

$n = 0$ or 1 ;

L and M are independently selected from the group consisting of hydrogen and methyl;

W is selected from the group consisting of Q; hydroxy; benzyloxy optionally substituted with halogen, $\text{C}_1 - \text{C}_8$ alkyl, $\text{C}_1 - \text{C}_8$ alkoxy, $\text{C}_3 - \text{C}_8$ cycloalkyl, $\text{C}_3 - \text{C}_8$ cycloalkoxy and hydroxy; aryl; heteroaryl; and a heterocyclic ring;

provided that when R_3 is methyl, R_8 is not hydrogen;

and pharmaceutically acceptable salts thereof.

Claim 7. (Withdrawn) The pharmaceutical compound of claim 6 wherein R_3 is benzyl.

Claim 8. (Withdrawn) The pharmaceutical compound of claim 6 wherein R_3 is benzyl substituted with an alkoxy and a cycloalkoxy group.

Claim 9. (Withdrawn) The pharmaceutical compound of claim 6 wherein R_3 is benzyl substituted with benzyloxy.

Claim 10. (Withdrawn) The pharmaceutical compound of claim 6 which is selected from the group consisting of:

3-butyl-hypoxanthine;

3-butyl-thiohypoxanthine;

3-ethyl-hypoxanthine;


3-ethyl-thiohypoxanthine;

3,8-diethyl-hypoxanthine;

3,8-diethyl-thiohypoxanthine;
 3-ethyl-8-cyclopropyl-hypoxanthine;
 3-ethyl-8-cyclopropyl-thiohypoxanthine;
 3-propyl-hypoxanthine;
 3-hexyl-hypoxanthine;
 3-hexyl-thiohypoxanthine;
 3-benzyl-hypoxanthine;
 3-benzyl-thiohypoxanthine;
 3-(4-methyl-butyl)-hypoxanthine;
 3-(4-methyl-butyl)-thiohypoxanthine;
 3-(2-methyl-butyl)-hypoxanthine;
 3-(2-methyl-butyl)-thiohypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-hydroxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethylene)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(benzyloxymethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1(4-methoxybenzyloxy)-1-methyl-
 ethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1(4-fluorobenzyloxy)-1-methyl-
 ethyl)-hypoxanthine;
 3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;
 3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-hydroxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(5-methyl-benzdioxole)-8-(1-methyl-ethyl)-hypoxanthine;

3-(4-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-(4-fluorobenzoyloxy)-1-methyl-ethyl)-
 hypoxanthine;
 and pharmaceutically acceptable salts thereof.

Claim 11. (Withdrawn) A method of treating a mammal suffering from a disease state selected from the group consisting of asthma, allergies, inflammation, depression, dementia and disease states associated with abnormally high physiologic levels of cytokine, comprising administering an effective amount of a compound of the formula:




wherein;

$R_6 = S$ or O

R_3 and R_8 are independently selected from the group consisting of $C_1 - C_8$ linear or branched alkyl; $C_2 - C_8$ linear or branched alkene; $C_2 - C_8$ linear or branched alkyne; C_{3-8} cycloalkyl; Q; and K; wherein

Q has the general formula:



wherein;


$n = 0$ or 1 ;

$Z =$ a bond, C, N, O or S;

A and B can form a ring by adding 1-3 carbons when $Z =$ C, N, O or S; and

A and B are not in a ring when $Z =$ a bond, wherein A and B are independently selected from the group consisting of hydrogen; halogen; $C_1 - C_8$ alkyl; $C_1 - C_8$ alkoxy; $C_3 - C_8$ cycloalkyl; $C_3 - C_8$ cycloalkoxy; hydroxy; phenyl; benzyl; and benzyloxy; wherein said phenyl, benzyl and benzyloxy are optionally substituted with halogen, $C_1 - C_8$ alkyl, $C_1 - C_8$ alkoxy, $C_3 - C_8$ cycloalkyl, $C_3 - C_8$ cycloalkoxy and hydroxy;

K has the general formula:



wherein;

$n = 0$ or 1 ;

L and M are independently selected from the group consisting of hydrogen and methyl;

W is selected from the group consisting of Q; hydroxy; benzyloxy optionally substituted with halogen, $C_1 - C_8$ alkyl, $C_1 - C_8$ alkoxy, $C_3 - C_8$ cycloalkyl, $C_3 - C_8$ cycloalkoxy and hydroxy; aryl; heteroaryl; and a heterocyclic ring;

provided that when R_3 is methyl, R_8 is not hydrogen;

and pharmaceutically acceptable salts thereof.

Claim 12. (Withdrawn) The method of claim 11 wherein R_3 is benzyl.

Claim 13. (Withdrawn) The method of claim 11 wherein R_3 is benzyl substituted with an alkoxy and a cycloalkoxy group.

Claim 14. (Withdrawn) The method of claim 11 wherein R₃ is benzyl substituted with benzyloxy.

Claim 15. (Withdrawn) The method of claim 11 which is selected from the group consisting of:

- 3-butyl-hypoxanthine;
- 3-butyl-thiohypoxanthine;
- 3-ethyl-hypoxanthine;
- 3-ethyl-thiohypoxanthine;
- 3,8-diethyl-hypoxanthine;
- 3,8-diethyl-thiohypoxanthine;
- 3-ethyl-8-cyclopropyl-hypoxanthine;
- 3-ethyl-8-cyclopropyl-thiohypoxanthine;
- 3-propyl-hypoxanthine;
- 3-hexyl-hypoxanthine;
- 3-hexyl-thiohypoxanthine;
- 3-benzyl-hypoxanthine;
- 3-benzyl-thiohypoxanthine;
- 3-(4-methyl-butyl)-hypoxanthine;
- 3-(4-methyl-butyl)-thiohypoxanthine;
- 3-(2-methyl-butyl)-hypoxanthine;
- 3-(2-methyl-butyl)-thiohypoxanthine;
- 3-(3-cyclopentyloxy-4-methoxy-benzyl)-hypoxanthine;
- 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-hydroxy-1-methyl-ethyl)-hypoxanthine;
- 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethylene)-hypoxanthine;
- 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;
- 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(benzyloxymethyl)-hypoxanthine;
- 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
- 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1(4-methoxybenzyloxy)-1-methyl-ethyl)-hypoxanthine;

3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-ethyl)-hypoxanthine;

3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;

3-(3-4-dimethoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;

3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-hydroxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-4-dimethoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(5-methyl-benzdioxole)-8-(1-methyl-ethyl)-hypoxanthine;

3-(4-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;


3-(4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-4-dimethoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-ethyl)-hypoxanthine;

and pharmaceutically acceptable salts thereof.

Claim 16. (Currently Amended) The pharmaceutical composition of claim 1, wherein said solid dosage form is selected from the group consisting of tablets, gelcaps, capsules, caplets, granules, and lozenges ~~and bulk powders~~.

Claim 17. (Previously Presented) A pharmaceutical composition comprising a compound of the formula:



in an effective amount to inhibit the PDE-IV enzyme upon administration to a human patient,

wherein;


$R_6 = S$ or O

R_3 is selected from the group consisting of $C_1 - C_8$ linear or branched alkyl; $C_2 - C_8$ linear or branched alkene; $C_2 - C_8$ linear or branched alkyne; C_{3-8} cycloalkyl; Q ; and K ;

R_8 is selected from the group consisting of $C_1 - C_8$ linear or branched alkyl; $C_2 - C_8$ linear or branched alkene; $C_2 - C_8$ linear or branched alkyne; C_{3-8} cycloalkyl; Q ; and K ;

wherein

Q has the general formula:



wherein;


$n = 0$ or 1 ;

$Z =$ a bond, CH_2 , NH , O or S ;

A and B can form a ring by adding 1-3 CH_2 groups when $Z = CH_2$, NH , O or S ; and

A and B are not in a ring when $Z =$ a bond, wherein A and B are independently selected from the group consisting of hydrogen; halogen; $C_1 - C_8$ alkyl; $C_1 - C_8$ alkoxy; $C_3 - C_8$ cycloalkyl; $C_3 - C_8$ cycloalkoxy; hydroxy; phenyl; benzyl; and benzyloxy; wherein said phenyl, benzyl and benzyloxy are optionally substituted with halogen, $C_1 - C_8$ alkyl, $C_1 - C_8$ alkoxy, $C_3 - C_8$ cycloalkyl, $C_3 - C_8$ cycloalkoxy and hydroxy;

K has the general formula:



wherein;

$n = 0$ or 1 ;

L and M are independently selected from the group consisting of hydrogen and methyl;

W is selected from the group consisting of Q; hydroxy; benzyloxy optionally substituted with halogen, $\text{C}_1 - \text{C}_8$ alkyl, $\text{C}_1 - \text{C}_8$ alkoxy, $\text{C}_3 - \text{C}_8$ cycloalkyl, $\text{C}_3 - \text{C}_8$ cycloalkoxy and hydroxy; aryl; heteroaryl; and a heterocyclic ring;

provided that when R_3 is methyl, R_8 is not hydrogen;

and pharmaceutically acceptable salts thereof,

and a pharmaceutically acceptable excipient;

said composition in the form of a liquid dosage form selected from the group consisting of emulsions and suspensions.

Claim 18. (Previously presented) The pharmaceutical composition of claim 17, wherein R_3 is benzyl.

Claim 19. (Previously presented) The pharmaceutical composition of claim 17, wherein R_3 is benzyl substituted with an alkoxy and a cycloalkoxy.

Claim 20. (Currently amended) The pharmaceutical composition of claim 17, wherein said compound is selected from the group consisting of:

~~3-butyl-hypoxanthine;~~

~~3-butyl-thiohypoxanthine;~~

~~3-ethyl-hypoxanthine;~~

~~3-ethyl-thiohypoxanthine;~~


3,8-diethyl-hypoxanthine;

3,8-diethyl-thiohypoxanthine;

3-ethyl-8-cyclopropyl-hypoxanthine;
 3-ethyl-8-cyclopropyl-thiohypoxanthine;
~~3-propyl-hypoxanthine;~~
~~3-hexyl-hypoxanthine;~~
~~3-hexyl-thiohypoxanthine;~~
~~3-benzyl-hypoxanthine;~~
~~3-benzyl-thiohypoxanthine;~~
~~3-(4-methyl-butyl)-hypoxanthine;~~
~~3-(4-methyl-butyl)-thiohypoxanthine;~~
~~3-(2-methyl-butyl)-hypoxanthine;~~
~~3-(2-methyl-butyl)-thiohypoxanthine;~~
~~3-(3-cyclopentyloxy-4-methoxy-benzyl)-hypoxanthine;~~
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-hydroxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethylene)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(benzyloxymethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-methoxybenzyloxy)-1-methyl-
 ethyl)-hypoxanthine;
 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-
 ethyl)-hypoxanthine;
 3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-
 hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-benzyloxy-1-methyl-ethyl)-hypoxanthine;
 3-(3-benzyloxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-hydroxy-4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(1,3-benzdioxole-5-methyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(4-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;

3-(3-chloro-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(4-methoxy-benzyl)-8-(1-methyl-ethyl)-hypoxanthine;
 3-(3-4-dimethoxy-benzyl)-8-(1-(4-fluorobenzyloxy)-1-methyl-ethyl)-
 hypoxanthine;
 and pharmaceutically acceptable salts thereof.

Claim 21. (Previously presented) A pharmaceutical composition comprising an active agent consisting essentially of at least one compound of the formula:



wherein;


R₆ = S or O

R₃ is selected from the group consisting of C₁ – C₈ linear or branched alkyl; C₂ – C₈ linear or branched alkene; C₂ – C₈ linear or branched alkyne; C₃₋₈ cycloalkyl; Q; and K;

R₈ is selected from the group consisting of C₁ – C₈ linear or branched alkyl; C₂ – C₈ linear or branched alkene; C₂ – C₈ linear or branched alkyne; C₃₋₈ cycloalkyl; Q; and K;

wherein

Q has the general formula:



wherein;


$n = 0$ or 1 ;

$Z =$ a bond, CH_2 , NH , O or S ;

A and B can form a ring by adding 1-3 CH_2 groups when $Z = \text{CH}_2$, NH , O or S ; and

A and B are not in a ring when $Z =$ a bond, wherein A and B are independently selected from the group consisting of hydrogen; halogen; $\text{C}_1 - \text{C}_8$ alkyl; $\text{C}_1 - \text{C}_8$ alkoxy; $\text{C}_3 - \text{C}_8$ cycloalkyl; $\text{C}_3 - \text{C}_8$ cycloalkoxy; hydroxy; phenyl; benzyl; and benzyloxy; wherein said phenyl, benzyl and benzyloxy are optionally substituted with halogen, $\text{C}_1 - \text{C}_8$ alkyl, $\text{C}_1 - \text{C}_8$ alkoxy, $\text{C}_3 - \text{C}_8$ cycloalkyl, $\text{C}_3 - \text{C}_8$ cycloalkoxy and hydroxy;

K has the general formula:



wherein;

$n = 0$ or 1 ;

L and M are independently selected from the group consisting of hydrogen and methyl;

W is selected from the group consisting of Q ; hydroxy; benzyloxy optionally substituted with halogen, $\text{C}_1 - \text{C}_8$ alkyl, $\text{C}_1 - \text{C}_8$ alkoxy, $\text{C}_3 - \text{C}_8$ cycloalkyl, $\text{C}_3 - \text{C}_8$ cycloalkoxy and hydroxy; aryl; heteroaryl; and a heterocyclic ring;

provided that when R_3 is methyl, R_8 is not hydrogen;

and pharmaceutically acceptable salts thereof;

and at least one pharmaceutically acceptable excipient, said composition in the form of a solid dosage form.